BioAge Labs, Inc. announced additional positive interim data from the ongoing Phase 1 clinical trial evaluating BGE-102, a novel NLRP3 inhibitor for cardiovascular risk.
The interim results showed significant reductions in inflammatory markers and a favorable safety profile for BGE-102.
BGE-102 demonstrated rapid and profound reduction in inflammatory markers, with 86% reduction in hsCRP at Day 14.
Promising Results
BGE-102 achieved a remarkable 86% reduction in hsCRP levels, with 93% of participants reaching normalized levels below 2 mg/L.
IL-6 Reduction
Significant reductions in IL-6 were observed, a key driver of systemic inflammation and cardiovascular risk.
Fibrinogen Reduction
BGE-102 showed a 30% reduction in fibrinogen, an independent predictor of cardiovascular events.
- BGE-102 showed rapid onset of effect with participants reaching desired hsCRP levels within days.
- The results support BGE-102 as a potential best-in-class oral therapy to directly address inflammation in cardiovascular patients.
The positive interim data for BGE-102 in reducing inflammatory markers and providing a favorable safety profile are promising for further development. BioAge Labs is moving forward with Phase 2a study initiation.